Dr. Goel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Yawkey 12, Dana-Farber Cancer Institute
Boston, MA 02215Phone+1 617-335-3937- Is this information wrong?
Education & Training
The University of Adelaide Faculty of Health SciencesClass of 1996
Certifications & Licensure
MA State Medical License 2018 - 2024
Clinical Trials
- Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Start of enrollment: 2017 May 26
Publications & Presentations
PubMed
- 24 citationsExploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancerShom Goel, R John Simes, Jane Beith
Asia-Pacific Journal of Clinical Oncology. 2011-09-01 - 12 citationsStereotactic radiotherapy for oligoprogressive ER-positive breast cancer (AVATAR).Reem Alomran, Michelle White, Melissa Bruce, Mathias Bressel, Susan Roache
BMC Cancer. 2021-03-23 - 193 citationsCDK4/6 inhibition in breast cancer: current practice and future directions.Sonia Pernas, Sara M. Tolaney, Eric P. Winer, Shom Goel
Therapeutic Advances in Medical Oncology. 2018-07-17
Press Mentions
Breast Cancer Updates from ESMO 2022September 21st, 2022
Studies Highlight ‘Potential New Targets for Immunotherapy’August 22nd, 2017
Drug Combination Drives HER2-Positive Breast Cancer Brain Metastases into Long-Term Remission in Mouse StudyJune 6th, 2016- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
